Plasma Folate Level and High‐Dose Folate Supplementation Predict Sulfadoxine‐Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria
Author(s) -
Anna Maria van Eijk,
Peter Ouma,
John Williamson,
Feiko O. ter Kuile,
Monica E. Parise,
Kephas Otieno,
Mary J. Hamel,
John Ayisi,
Simon Kariuki,
Piet A. Kager,
Laurence Slutsker
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/592715
Subject(s) - sulfadoxine/pyrimethamine , malaria , medicine , sulfadoxine , pyrimethamine , pregnancy , obstetrics , physiology , immunology , biology , plasmodium falciparum , genetics
Sulfadoxine-pyrimethamine (SP) inhibits folate metabolism by the malaria parasite. We investigated the association between folate levels and SP failure in pregnant women. Data from a trial to assess the effect that folate supplementation has on SP failure in 467 pregnant women were analyzed. Plasma folate levels were determined at enrollment and at day 7. High baseline folate levels, high parasite densities, and age <20 years were risk factors for SP failure. High-dose (5 mg daily) folate supplementation or high folate levels at day 7 were independent risk factors. Therefore, pregnant women receiving SP should receive low-/moderate-dose folate supplementation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom